Evan J H Lewis1, Leif E Lovblom1, Maryam Ferdousi2, Elise M Halpern1, Maria Jeziorska2, Daniele Pacaud3, Nicola Pritchard4, Cirous Dehghani4, Katie Edwards4, Sangeetha Srinivasan4, Roni Mintz Shtein5, Nathan Efron4, Mitra Tavakoli2,6, Vera Bril7, Rayaz Ahmed Malik8,9, Bruce A Perkins10. 1. Division of Endocrinology, Leadership Sinai Centre for Diabetes, University of Toronto, Toronto, Canada. 2. Faculty of Biology, Medicine and Health, University of Manchester, Manchester, U.K. 3. Alberta Children's Hospital, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Canada. 4. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. 5. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI. 6. Institute of Health Research, University of Exeter Medical School, Exeter, U.K. 7. Ellen and Martin Prosserman Centre for Neuromuscular Disorders, Division of Neurology, University Health Network, University of Toronto, Toronto, Canada. 8. Institute of Cardiovascular Medicine, University of Manchester, Manchester, U.K. 9. Weill Cornell Medicine-Qatar, Doha, Qatar. 10. Division of Endocrinology, Leadership Sinai Centre for Diabetes, University of Toronto, Toronto, Canada bruce.perkins@sinaihealthsystem.ca.
Abstract
OBJECTIVE: Corneal nerve fiber length (CNFL) represents a biomarker for diabetic distal symmetric polyneuropathy (DSP). We aimed to determine the reference distribution of annual CNFL change, the prevalence of abnormal change in diabetes, and its associated clinical variables. RESEARCH DESIGN AND METHODS: We examined 590 participants with diabetes (399 with type 1 diabetes [T1D] and 191 with type 2 diabetes [T2D]) and 204 control patients without diabetes with at least 1 year of follow-up and classified them according to rapid corneal nerve fiber loss (RCNFL) if CNFL change was below the 5th percentile of the control patients without diabetes. RESULTS: Control patients without diabetes were 37.9 ± 19.8 years old, had median follow-up of three visits over 3.0 years, and mean annual change in CNFL was -0.1% (90% CI -5.9% to 5.0%). RCNFL was defined by values exceeding the 5th percentile of 6% loss. Participants with T1D were 39.9 ± 18.7 years old, had median follow-up of three visits over 4.4 years, and mean annual change in CNFL was -0.8% (90% CI -14.0% to 9.9%). Participants with T2D were 60.4 ± 8.2 years old, had median follow-up of three visits over 5.3 years, and mean annual change in CNFL was -0.2% (90% CI -14.1% to 14.3%). RCNFL prevalence was 17% overall and was similar by diabetes type (64 T1D [16.0%], 37 T2D [19.4%], P = 0.31). RNCFL was more common in those with baseline DSP (47% vs. 30% in those without baseline DSP, P = 0.001), which was associated with lower peroneal conduction velocity but not with baseline HbA1c or its change over follow-up. CONCLUSIONS: An abnormally rapid loss of CNFL of 6% per year or more occurs in 17% of diabetes patients. RCNFL may identify patients at highest risk for the development and progression of DSP.
OBJECTIVE: Corneal nerve fiber length (CNFL) represents a biomarker for diabetic distal symmetric polyneuropathy (DSP). We aimed to determine the reference distribution of annual CNFL change, the prevalence of abnormal change in diabetes, and its associated clinical variables. RESEARCH DESIGN AND METHODS: We examined 590 participants with diabetes (399 with type 1 diabetes [T1D] and 191 with type 2 diabetes [T2D]) and 204 control patients without diabetes with at least 1 year of follow-up and classified them according to rapid corneal nerve fiber loss (RCNFL) if CNFL change was below the 5th percentile of the control patients without diabetes. RESULTS: Control patients without diabetes were 37.9 ± 19.8 years old, had median follow-up of three visits over 3.0 years, and mean annual change in CNFL was -0.1% (90% CI -5.9% to 5.0%). RCNFL was defined by values exceeding the 5th percentile of 6% loss. Participants with T1D were 39.9 ± 18.7 years old, had median follow-up of three visits over 4.4 years, and mean annual change in CNFL was -0.8% (90% CI -14.0% to 9.9%). Participants with T2D were 60.4 ± 8.2 years old, had median follow-up of three visits over 5.3 years, and mean annual change in CNFL was -0.2% (90% CI -14.1% to 14.3%). RCNFL prevalence was 17% overall and was similar by diabetes type (64 T1D [16.0%], 37 T2D [19.4%], P = 0.31). RNCFL was more common in those with baseline DSP (47% vs. 30% in those without baseline DSP, P = 0.001), which was associated with lower peroneal conduction velocity but not with baseline HbA1c or its change over follow-up. CONCLUSIONS: An abnormally rapid loss of CNFL of 6% per year or more occurs in 17% of diabetespatients. RCNFL may identify patients at highest risk for the development and progression of DSP.
Authors: Danièle Pacaud; Kenneth G Romanchuk; Mitra Tavakoli; Claire Gougeon; Heidi Virtanen; Maryam Ferdousi; Alberto Nettel-Aguirre; Jean K Mah; Rayaz A Malik Journal: Invest Ophthalmol Vis Sci Date: 2015-08 Impact factor: 4.799
Authors: J D England; G S Gronseth; G Franklin; R G Miller; A K Asbury; G T Carter; J A Cohen; M A Fisher; J F Howard; L J Kinsella; N Latov; R A Lewis; P A Low; A J Sumner Journal: Neurology Date: 2005-01-25 Impact factor: 9.910
Authors: Drew A Hume; Leif Erik Lovblom; Ausma Ahmed; Emily Yeung; Andrej Orszag; Tae Maen Shin; Vera Bril; Bruce A Perkins Journal: Diabetes Res Clin Pract Date: 2012-05-10 Impact factor: 5.602
Authors: Mitra Tavakoli; Maryam Ferdousi; Ioannis N Petropoulos; Julie Morris; Nicola Pritchard; Andrey Zhivov; Dan Ziegler; Danièle Pacaud; Kenneth Romanchuk; Bruce A Perkins; Leif E Lovblom; Vera Bril; J Robinson Singleton; Gordon Smith; Andrew J M Boulton; Nathan Efron; Rayaz A Malik Journal: Diabetes Care Date: 2015-01-29 Impact factor: 19.112
Authors: Gavasker A Sivaskandarajah; Elise M Halpern; Leif E Lovblom; Alanna Weisman; Steven Orlov; Vera Bril; Bruce A Perkins Journal: Diabetes Care Date: 2013-04-11 Impact factor: 19.112
Authors: Ioannis N Petropoulos; Uazman Alam; Hassan Fadavi; Omar Asghar; Patrick Green; Georgios Ponirakis; Andrew Marshall; Andrew J M Boulton; Mitra Tavakoli; Rayaz A Malik Journal: Diabetes Care Date: 2013-07-22 Impact factor: 19.112
Authors: Fu-Shin X Yu; Patrick S Y Lee; Lingling Yang; Nan Gao; Yangyang Zhang; Alexander V Ljubimov; Ellen Yang; Qingjun Zhou; Lixin Xie Journal: Prog Retin Eye Res Date: 2022-01-04 Impact factor: 19.704
Authors: Hoda Gad; Bara Al-Jarrah; Saras Saraswathi; Ioannis N Petropoulos; Georgios Ponirakis; Adnan Khan; Parul Singh; Souhaila Al Khodor; Mamoun Elawad; Wesam Almasri; Hatim Abdelrahman; Ahmed Elawwa; Amel Khalifa; Ahmed Shamekh; Fawziya Al-Khalaf; Goran Petrovski; Mahmoud Al Zyoud; Maryam Al Maadheed; Mohamed A Hendaus; Khalid Hussain; Anthony K Akobeng; Rayaz A Malik Journal: J Diabetes Investig Date: 2020-07-07 Impact factor: 4.232
Authors: Jamie Burgess; Bernhard Frank; Andrew Marshall; Rashaad S Khalil; Georgios Ponirakis; Ioannis N Petropoulos; Daniel J Cuthbertson; Rayaz A Malik; Uazman Alam Journal: Diagnostics (Basel) Date: 2021-01-24
Authors: Frank G Preston; Yanda Meng; Jamie Burgess; Maryam Ferdousi; Shazli Azmi; Ioannis N Petropoulos; Stephen Kaye; Rayaz A Malik; Yalin Zheng; Uazman Alam Journal: Diabetologia Date: 2021-11-21 Impact factor: 10.122
Authors: Bruce A Perkins; Leif Erik Lovblom; Evan J H Lewis; Vera Bril; Maryam Ferdousi; Andrej Orszag; Katie Edwards; Nicola Pritchard; Anthony Russell; Cirous Dehghani; Danièle Pacaud; Kenneth Romanchuk; Jean K Mah; Maria Jeziorska; Andrew Marshall; Roni M Shtein; Rodica Pop-Busui; Stephen I Lentz; Mitra Tavakoli; Andrew J M Boulton; Nathan Efron; Rayaz A Malik Journal: Diabetes Care Date: 2021-07-01 Impact factor: 17.152